Modified-Release Oral Minoxidil for Sustained Therapeutic Levels

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for hair loss, such as topical minoxidil, often result in adverse effects and do not provide sustained therapeutic levels of the drug, leading to inefficiencies in hair regrowth promotion.

Innovation Solution

A modified release formulation of minoxidil or its pharmaceutically acceptable salt, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, achieving a Tmax of 30 to 360 minutes and a Cmax of 0.25 ng/ml to 20 ng/ml, minimizing adverse effects and optimizing hair regrowth treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If topical minoxidil is used for hair loss treatment, then hair regrowth promotion is achieved, but adverse effects occur and therapeutic levels are not sustained

Engineering Contradiction:

Improvetherapeutic level sustainabilityVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the drug delivery process into multiple phases using a modified release formulation that releases minoxidil in a controlled manner over time, rather than as a single immediate dose. This segmentation of release timing maintains sustained therapeutic levels while reducing peak-related adverse effects

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs a dynamic release profile where the formulation adjusts drug release rates based on therapeutic needs, transitioning from initial release to sustained maintenance levels. This dynamic control optimizes therapeutic effectiveness while minimizing adverse effects throughout the dosing period

Inventive Principle:

Principle #15Dynamics

2Speed

If immediate release formulation is used, then rapid drug availability is achieved, but adverse effects increase and therapeutic levels are not maintained

Engineering Contradiction:

Improvedrug availability speedVSAvoidtherapeutic level duration

Core Design Contradiction:

SpeedVSDuration of action of moving object

Solution Approach 1:

The patent implements periodic action through a modified release formulation that provides initial rapid drug availability followed by sustained periodic release over an extended period. This creates a biphasic release pattern that satisfies both rapid onset and prolonged duration requirements

Inventive Principle:

Principle #19Periodic action

Solution Approach 2:

The patent ensures continuity of useful action by designing a formulation that maintains minoxidil release over an extended period (at least 12 hours), preventing therapeutic level drops while avoiding complete immediate release. This continuous action sustains hair regrowth promotion without interruption

Inventive Principle:

Principle #20Continuity of useful action

3Productivity

If high dose minoxidil is administered, then hair regrowth effectiveness is improved, but adverse effects increase

Engineering Contradiction:

Improvehair regrowth effectivenessVSAvoidadverse effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the temporal distribution parameter of drug delivery by using modified release technology. This transforms a single high-dose administration into a distributed release pattern, maintaining high cumulative effectiveness while reducing peak concentration-related adverse effects through parameter optimization

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250302835A1Compositions and methods of use for modified release minoxidil

Publication Date: 2025.10.02 VERADERMICS INC

AI summary

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.